THOUSAND OAKS, Calif. (Aug. 19, 2014) – Amgen (NASDAQ:AMGN) today announced that Elliott M. Levy, M.D., has been named senior vice president, Global Development, effective Sept. 8, 2014. Levy comes to Amgen from Bristol-Myers Squibb (BMS), where he most recently served as senior vice president and head, Specialty Development.
“Elliott brings a wealth of development and leadership experience to his new role at Amgen,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “His track record shows his success in leading major clinical development programs, and we’re confident that he will help Amgen to serve patients by advancing the large number of potential new medicines in our late-stage pipeline.”
In his 17-year career at BMS, Levy served in a range of senior positions spanning the spectrum of clinical development and related responsibilities. Prior to his current role, Levy led Global Pharmacovigilance and Epidemiology at BMS. Other previous roles included Cardiovascular Clinical Development, Immunoscience Clinical Research, and Global Clinical Research Operations.
Levy is a graduate of Yale College and School of Medicine, where he was Chief Medical Resident and trained in Internal Medicine and Nephrology. He completed fellowship training in clinical research through the Robert Wood Johnson Clinical Scholars program. Before joining BMS, he was a member of the Renal Division at Brigham and Women's Hospital in Boston, where he was an investigator in federally-sponsored outcomes research as well as industry-sponsored clinical trials.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
CONTACT: Amgen, Thousand Oaks
Kristen Davis, 805-447-3008 (media)
Arvind Sood, 805-447-1060 (investors)